Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL) with genetic alterations of BCL-2, KMT2B, and KMT6.
|
30693983 |
2019 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL.
|
30850381 |
2019 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
A recent phase I first-in-human study of the BCL-2 inhibitor venetoclax in non-Hodgkin lymphoma showed an overall response rate of 44%.
|
29666304 |
2018 |
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Conclusion Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes.
|
28095146 |
2017 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study explored whether Bcl-2, targeted by miR-21, would affect the development of NHL.
|
29067124 |
2017 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
The expressions of EBV (+), p53(+), Bcl-2(+), Rb(-) and c-Myc(+) were determined and compared among different subtypes and stages of NHLs of observation group.
|
27049262 |
2016 |
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
DNA was extracted from archival CPs of B-cell NHL cases with previous fluorescence in situ hybridization (FISH) assays for MYC rearrangement and/or IGH/BCL-2 translocation.
|
25807917 |
2015 |
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thirty-two patients diagnosed with non-Hodgkin lymphoma with concurrent MYC and BCL2 translocations from 2003 to 2013 were identified.
|
25656914 |
2015 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
CTD_human |
Thus, bcl-2 overexpression might be considered a new independent prognostic parameter in NHL, aiding in the identification of patients at risk for treatment failure.
|
26239085 |
2015 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overexpression of anti-apoptotic BCL-2 family members is a hallmark of many lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) that can be targeted with small molecule inhibitors.
|
25590803 |
2015 |
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus, bcl-2 overexpression might be considered a new independent prognostic parameter in NHL, aiding in the identification of patients at risk for treatment failure.
|
26239085 |
2015 |
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
There appeared to be an impact of the BCL2 - 938AA genotype on advanced stage and - 248AG + AA genotypes on tumor size in NHL.
|
24024471 |
2014 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
We developed a (177)Lu-labeled bcl-2 antisense peptide nucleic acid (PNA)-peptide conjugate designed for dual modality NHL therapy, consisting of a radiopharmaceutical capable of simultaneously down-regulating apoptotic resistance and delivering cytotoxic internally emitted radiation.
|
24267052 |
2014 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
MYC/BCL2 double hit lymphoma (DHL) is a rare, recently recognised and highly aggressive subtype of non-Hodgkin lymphoma, with an affinity to involve the central nervous system and the head and neck either at initial presentation or during relapse.
|
23932423 |
2014 |
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In our study, we investigated the prognostic significance of CD95, BCL2, and P53 expression in extranodal non-Hodgkin's lymphoma (NHL).
|
20352431 |
2010 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tobacco exposures were not clearly associated with t(14; 18)-positive NHL or bcl-2 case-subtypes.
|
20232134 |
2010 |
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The t(14;18)(q32;q21) translocation is the most commonly observed chromosomal translocation in non-Hodgkin's lymphoma (NHL), resulting in constitutive Bcl-2 expression and apoptosis inhibition.
|
20855536 |
2010 |
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma.
|
18929412 |
2009 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
This indicates that primers for bcl-2 gene must include icr primer, whenever the bcl-2 gene is being evaluated for B-cell NHL in this part of the world and this might reduce the variability of frequency of bcl-2 gene rearrangement within and between different regions.
|
19537891 |
2009 |
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Some evidence suggests that IL-10 might be associated with the progression of T-cell NHLs and that IL-10 may be involved in a rescue effect, protecting T cells from apoptotic cell death associated with upregulated bcl-2 expression.
|
17408400 |
2007 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multiplex PCR for the detection of BCL-1/IGH and BCL-2/IGH gene rearrangements--clinical validation in a prospective study of blood and bone marrow in 258 patients with or suspected of non-Hodgkin's lymphoma.
|
17438702 |
2007 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Bcl-2 has been implicated in conferring resistance to chemotherapy in non-Hodgkin's lymphoma and is therefore a candidate prognostic marker in DLBCL.
|
16796775 |
2006 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials are exploring the role of Bcl-2 downregulation with oblimersen (Bcl-2 antisense) in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
|
15784299 |
2005 |
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
These modifications induced by rituximab were in large part responsible for the down-regulation of the anti-apoptotic gene products Bcl-2/Bcl-xL and chemosensitization of the drug-resistant B-NHL cell lines to various drug-induced apoptosis.
|
15939340 |
2005 |
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These figures are similar to those reported in the West, and therefore bcl-2 gene rearrangement does not help in explaining the epidemiological differences of NHL between Jordan and the West.
|
15770300 |
2005 |